Cite
HARVARD Citation
Hutter, J. et al. (2022). First-in-human assessment of safety and immunogenicity of low and high doses of Plasmodium falciparum malaria protein 013 (FMP013) administered intramuscularly with ALFQ adjuvant in healthy malaria-naïve adults. Vaccine. 40 (40), pp. 5781-5790. [Online].